Oral Chinese Patent Mediciens for Lung Cancer:A Scoping Review of Clinical Evidence / 中国实验方剂学杂志
Chinese Journal of Experimental Traditional Medical Formulae
; (24): 204-213, 2022.
Article
ي Zh
| WPRIM
| ID: wpr-940404
المكتبة المسؤولة:
WPRO
ABSTRACT
This scoping review aimed to summarize the application information and clinical studies of oral Chinese patent medicines. The oral Chinese patent medicines in treating lung cancer were screened out by searching pf the drug directory, related guidelines, and medical information websites. The data including functions, application, ingredients, and prices of these medicines were collected. Six public databases were searched with the time interval of establishment to August 22, 2021 for collection of the clinical studies of oral Chinese patent medicines in the treatment of lung cancer. The expert consensuses, systematic reviews, randomized controlled trials, non-randomized controlled trials, and non-controlled trials were selected for analysis. A total of 104 oral Chinese patent medicines were screened out, including 31 capsules, 16 granules, 20 oral liquids, 17 tablets, 17 pills, and 3 ointments, in which altogether 198 herbal medicines were involved. The single-dose prices of 2, 36, and 66 medicines were > CNY 100, CNY 10-100, and < CNY 10, respectively. There were 410 clinical studies associated with 48 oral Chinese patent medicines, which were published from 1986 to 2021. These publications included 1 expert consensus, 21 systematic reviews, 277 randomized controlled trials, 87 non-randomized controlled trials, and 24 non-controlled trials. In the clinical studies, the Chinese patent medicines were usually applied in combination with radiotherapy and chemotherapy. The evaluation of primary outcomes focused on 9 indicators including clinical efficacy, quality of life, and incidence of side effects. In conclusion, the oral Chinese patent medicines demonstrated significant advantages in the treatment of lung cancer, and the relevant clinical trials were increasing year by year, with multiple outcome indicators being evaluated. More comprehensive and standardized clinical studies need to be designed for oral Chinese patent medicines in treating lung cancer in the future.
النص الكامل:
1
الفهرس:
WPRIM
نوع الدراسة:
Clinical_trials
/
Guideline
/
Systematic_reviews
اللغة:
Zh
مجلة:
Chinese Journal of Experimental Traditional Medical Formulae
السنة:
2022
نوع:
Article